Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

SCR7

SKU: orb1226138

Description

SCR7 is a specific inhibitor of nonhomologous end-joining (NHEJ), blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I; inhibits NHEJ in a Ligase IV-dependent manner within cells, causes accumulation of double-strand breaks (DSBs), and activates the intrinsic apoptotic pathway; decreases cell proliferation of MCF7, A549, and HeLa with IC50 of 40, 34, and 44 uM, respectively; increases the efficacy of DSB-inducing therapeutic modalities in mouse xenografts; increases the efficiency of precise genome editing with CRISPR-Cas9 in mammalian cell lines and in mice.

Images & Validation

Key Properties

CAS Number1533426-72-0
MW334.395
Purity>98% (HPLC)
FormulaC18H14N4OS
SMILESO=C(C(/N=C/C1=CC=CC=C1)=C(/N=C/C2=CC=CC=C2)N3)NC3=S
TargetDNA/RNA Synthesis
SolubilityDMSO: ≥ 45 mg/mL

Bioactivity

In Vivo
SCR7 (SCR7 pyrazine; 10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment significantly reduces breast adenocarcinoma-induced tumor and increases lifespan. Animal model: BALB/c mice injected with breast adenocarcinoma cells. Dosage: 10 mg/kg. Administration: Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10). Result: Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan.
In Vitro
SCR7 (SCR7 pyrazine; 20-100 μM; 24 hours; MCF7 cells) treatment interferes with NHEJ in cells, leading to accumulation of unrepaired double-strand breaks (DSBs). SCR7 (SCR7 pyrazine) treatment shows a dose-dependent decrease in cell proliferation with IC50 values of 40 μM, 34 μM, 44 μM, 8.5 μM, 120 μM, 10 μM and 50 μM for MCF7, A549, HeLa, T47D, A2780, HT1080 and Nalm6 cells, respectively. In MCF7 cells, SCR7 (SCR7 pyrazine; 20, 40 μM) treatment increases phosphorylation of ATM and activates p53, decreases MDM2, BCL2, resulting in activation of proapoptotic proteins, PUMA and BAX. And the shorter fragments of MCL1, PARP1, Caspase 3, and Caspase 9 cleavage are upregulated in a dose-dependent manner. Western blot analysis. Cell line: MCF7 cells. Concentration: 20 μM, 40 μM, 100 μM. Incubation time: 24 hours. Result: Showed an increase in levels of gH2AX foci and protein.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

SCR-7

Similar Products

  • SCR7 [orb1696093]

    1533426-72-0

    334.4

    C18H14N4OS

    25 mg, 10 mg, 1 mg, 5 mg
  • SCR7 pyrazine [orb1307614]

    >98%

    14892-97-8

    332.4

    C18H12N4OS

    5 mg, 25 mg
  • SCR7 pyrazine [orb1223283]

    >98% (HPLC)

    14892-97-8

    332.38

    C18H12N4OS

    2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information